Local pharma

To the best of my knowledge, Pakistan has over 700 pharmaceutical companies, but they mainly focus on formulations rather than producing active ingredients, leading to a heavy reliance on imports. This dependency makes locally produced medicines more expensive than those in other regional countries like India. Factors like energy shortages and high utility rates also raise production costs in Pakistan. Additionally, import duties on raw materials and insufficient government backing for local manufacturing hinder competitiveness. The lack of stringent price controls and limited R&D investments further restrict innovation.

Most Pakistani manufacturers operate on a smaller scale, causing inefficiencies and higher unit costs. Currency devaluation also raises the cost of imported inputs, impacting final medicine prices. To address these structural challenges, Pakistan must invest in local production capabilities and develop supportive policies for its pharmaceutical sector.

Sajid Awan

Dubai

UAE